Publications by authors named "Margaux Faes"

Claim this Profile
M
Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes.
Xavier Mariette, Sven Borchmann, Sandrine Aspeslagh, Zoltan Szekanecz, Christina Charles-Schoeman, Margaux Faes

RMD Open· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study.
Brian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Margaux Faes

Aliment Pharmacol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactive medical and safety monitoring in clinical trials with clinDataReview: a validated and open-source reporting tool.
Laure Cougnaud, Margaux Faes, Dirk Van Krunckelsven, Arne De Roeck, Michela Pasetto

Front Med (Lausanne)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study.
Kenji Watanabe, Laurent Peyrin-Biroulet, Silvio Danese, Yasushi Fujitani, Margaux Faes

J Crohns Colitis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.
Séverine Vermeire, Brian G Feagan, Laurent Peyrin-Biroulet, Alessandra Oortwijn, Margaux Faes

J Crohns Colitis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.
Stefan Schreiber, Gerhard Rogler, Mamoru Watanabe, Séverine Vermeire, Christian Maaser, Margaux Faes

Aliment Pharmacol Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial.
Stefan Schreiber, Brian G Feagan, Laurent Peyrin-Biroulet, Séverine Vermeire, Margaux Faes

J Crohns Colitis· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis